Studies have indicated that Sig-1R activation reduces cardiac hypertrophy, prevents ventricular remodelling, decreases fibrosis, and improves functional recovery through various pathways that address pressure overload-induced myocardial dysfunction [6–8]. Here, SIGMAR1 is linked to cardiac hypertrophy.